author-photo

Eva Wagner

84

Papers

769

Citations

Citation Trend

Filter By

Papers (59) Sort By

Journal Conference Others

P-175: Outcomes of autologous-allogeneic vs autologous tandem approach followed by thalidomide maintenance for transplant-eligible patients with newly diagnosed multiple myeloma: a prospective phase II-study

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
MRD Status Impact on Secondary Acute Myeloid Leukemia Outcomes after Allogeneic Hematopoietic Cell Transplantation. A Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

2021
Show All
- Source
- Cite
- Save
Citations (0)
Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Immunohistochemical markers for histopathological diagnosis and differentiation of acute cutaneous graft-versus-host disease.

2021 Experimental Dermatology
Show All
- Source
- Cite
- Save
Citations (0)
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.

2020 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (161)
Safety Analysis of Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients (pts) with Steroid-Refractory (SR) Acute Graft-Vs-Host Disease (aGVHD) in the Randomized Phase 3 REACH2 Study

2020 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia - a study of the Acute Leukemia Working Party of the EBMT.

2020 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (0)
Conversion from MRD Positive to Negative Status in AML Patients in CR1 after Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

2020 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study

2020 Blood
Show All
- Source
- Cite
- Save
Citations (1)
A Single Dose of Donor Lymphocytes Depleted of Alloreactive T Cells (ATIR101) after Haploidentical HSCT Is Well-Tolerated and Efficacious: Pooled Analysis of Two Phase II Studies

2019 Biology of Blood and Marrow Transplantation
Show All
- Source
- Cite
- Save
Citations (1)